Law360 (August 13, 2019, 6:38 PM EDT) -- Landos Biopharma on Tuesday said investors handed over $60 million in its latest funding round, as the Covington & Burling LLP-guided autoimmune disease treatment developer aims to advance clinical trials for a leading drug candidate.
Blacksburg, Virginia-based Landos said RTW Investments and Perceptive Advisors LLC co-led the series-B funding round, while new investors Osage University Partners and PBM Capital also participated.
Landos markets itself as a clinical-stage biopharmaceutical company specializing in treatments for autoimmune diseases. The company’s leading drug candidate, known as BT-11, is in the midst of clinical trials and has shown promising results for the treatment of ulcerative colitis...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!